Design, Development, and Characterization of Imiquimod-Loaded Chitosan Films for Topical Delivery

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aldara™ (5% w/w imiquimod) topical cream is approved by the US FDA for the treatment of superficial basal cell carcinoma. However, the cream formulation suffers from dose variability, low drug availability due to the incomplete release, and poor patient compliance. To achieve sustained and complete release of imiquimod, chitosan films were prepared by casting using propylene glycol as a plasticizer. Chitosan films had appropriate physicochemical characteristics for wound dressing and excellent content uniformity and maintained the original physical form of imiquimod. Films were capable of releasing a defined dose of imiquimod over a period of 7 days. The bioactivity of imiquimod was not affected by its entrapment in chitosan matrix as indicated by the results of in vitro growth inhibition assay. In addition, the film formulation showed significantly (p ˂ 0.05) higher drug accumulation in the skin when compared to commercial cream formulation.

Original languageEnglish (US)
Article number58
JournalAAPS PharmSciTech
Volume20
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

imiquimod
Chitosan
cream
chitosan
patient compliance
drugs
propylene glycol
plasticizers
dosage
skin (animal)
animal injuries
growth retardation
carcinoma
Plasticizers
Propylene Glycol
Basal Cell Carcinoma
assays
Bandages
Patient Compliance
Pharmaceutical Preparations

Keywords

  • basal cell carcinoma
  • chitosan
  • film formulation
  • imiquimod
  • topical drug delivery

PubMed: MeSH publication types

  • Journal Article

Cite this

Design, Development, and Characterization of Imiquimod-Loaded Chitosan Films for Topical Delivery. / Layek, Buddhadev; Rahman Nirzhor, Saif S.; Rathi, Sneha; Kandimalla, Karunya K; Wiedmann, Timothy S; Prabha, Swayam.

In: AAPS PharmSciTech, Vol. 20, No. 2, 58, 01.02.2019.

Research output: Contribution to journalArticle

@article{38f99ce81649443abec5bbadfbfcc89c,
title = "Design, Development, and Characterization of Imiquimod-Loaded Chitosan Films for Topical Delivery",
abstract = "Aldara™ (5{\%} w/w imiquimod) topical cream is approved by the US FDA for the treatment of superficial basal cell carcinoma. However, the cream formulation suffers from dose variability, low drug availability due to the incomplete release, and poor patient compliance. To achieve sustained and complete release of imiquimod, chitosan films were prepared by casting using propylene glycol as a plasticizer. Chitosan films had appropriate physicochemical characteristics for wound dressing and excellent content uniformity and maintained the original physical form of imiquimod. Films were capable of releasing a defined dose of imiquimod over a period of 7 days. The bioactivity of imiquimod was not affected by its entrapment in chitosan matrix as indicated by the results of in vitro growth inhibition assay. In addition, the film formulation showed significantly (p ˂ 0.05) higher drug accumulation in the skin when compared to commercial cream formulation.",
keywords = "basal cell carcinoma, chitosan, film formulation, imiquimod, topical drug delivery",
author = "Buddhadev Layek and {Rahman Nirzhor}, {Saif S.} and Sneha Rathi and Kandimalla, {Karunya K} and Wiedmann, {Timothy S} and Swayam Prabha",
year = "2019",
month = "2",
day = "1",
doi = "10.1208/s12249-018-1288-5",
language = "English (US)",
volume = "20",
journal = "AAPS PharmSciTech",
issn = "1530-9932",
publisher = "American Association of Pharmaceutical Scientists",
number = "2",

}

TY - JOUR

T1 - Design, Development, and Characterization of Imiquimod-Loaded Chitosan Films for Topical Delivery

AU - Layek, Buddhadev

AU - Rahman Nirzhor, Saif S.

AU - Rathi, Sneha

AU - Kandimalla, Karunya K

AU - Wiedmann, Timothy S

AU - Prabha, Swayam

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Aldara™ (5% w/w imiquimod) topical cream is approved by the US FDA for the treatment of superficial basal cell carcinoma. However, the cream formulation suffers from dose variability, low drug availability due to the incomplete release, and poor patient compliance. To achieve sustained and complete release of imiquimod, chitosan films were prepared by casting using propylene glycol as a plasticizer. Chitosan films had appropriate physicochemical characteristics for wound dressing and excellent content uniformity and maintained the original physical form of imiquimod. Films were capable of releasing a defined dose of imiquimod over a period of 7 days. The bioactivity of imiquimod was not affected by its entrapment in chitosan matrix as indicated by the results of in vitro growth inhibition assay. In addition, the film formulation showed significantly (p ˂ 0.05) higher drug accumulation in the skin when compared to commercial cream formulation.

AB - Aldara™ (5% w/w imiquimod) topical cream is approved by the US FDA for the treatment of superficial basal cell carcinoma. However, the cream formulation suffers from dose variability, low drug availability due to the incomplete release, and poor patient compliance. To achieve sustained and complete release of imiquimod, chitosan films were prepared by casting using propylene glycol as a plasticizer. Chitosan films had appropriate physicochemical characteristics for wound dressing and excellent content uniformity and maintained the original physical form of imiquimod. Films were capable of releasing a defined dose of imiquimod over a period of 7 days. The bioactivity of imiquimod was not affected by its entrapment in chitosan matrix as indicated by the results of in vitro growth inhibition assay. In addition, the film formulation showed significantly (p ˂ 0.05) higher drug accumulation in the skin when compared to commercial cream formulation.

KW - basal cell carcinoma

KW - chitosan

KW - film formulation

KW - imiquimod

KW - topical drug delivery

UR - http://www.scopus.com/inward/record.url?scp=85059798363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059798363&partnerID=8YFLogxK

U2 - 10.1208/s12249-018-1288-5

DO - 10.1208/s12249-018-1288-5

M3 - Article

VL - 20

JO - AAPS PharmSciTech

JF - AAPS PharmSciTech

SN - 1530-9932

IS - 2

M1 - 58

ER -